IPO - Senti Biosciences, Inc.

Form Type: 424B5

Filing Date: 2025-03-31

Corporate Action: Ipo

Type: New

Accession Number: 000114036125011323

Filing Summary: Senti Biosciences, Inc. has filed a prospectus supplement for an offering of common stock with a total aggregate offering price of up to $17,500,000. The offering is being conducted under a sales agreement with Leerink Partners LLC, which will act as the sales agent. The company’s common stock is traded on The Nasdaq Capital Market under the symbol 'SNTI'. As of March 26, 2025, the last sale price of common stock was reported at $3.55 per share, with a public float of approximately $57.81 million as of March 19, 2025. The company intends to use the proceeds for working capital, clinical trials, and general corporate purposes. This offering may be made on an 'at the market' basis, allowing for variable pricing based on market conditions. The company has reported recurring losses, indicating substantial doubt about its ability to continue operations, with a noted accumulated deficit and concerns outlined by its auditing firm regarding its going concern status. Prospective investors are advised to review the risk factors associated with this investment as detailed within the document.

Form Type: S-3

Filing Date: 2025-03-21

Corporate Action: Ipo

Type: New

Accession Number: 000114036125009738

Filing Summary: Senti Biosciences, Inc. filed a registration statement on Form S-3 with the SEC for the public offering of 52,892,500 shares of its common stock by selling securityholders. This includes 21,157,000 shares arising from the conversion of Series A Convertible Preferred Stock and 31,735,500 shares that can be issued upon the exercise of warrants. The Series A Preferred Stock was issued at $2,250.00 per share and convertible into common stock at a price of $2.25 per share. The initial issuance of these securities occurred through a private placement transaction that raised approximately $47.6 million. The common stock will be listed on The Nasdaq Capital Market under the symbol 'SNTI'. Market conditions suggest that issuing these shares may impact the liquidity and trading of Senti’s securities, potentially resulting in significant dilution for current shareholders. All commissions from the sales will be borne by the selling securityholders, while the company will cover costs related to the registration of these shares.